These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 5157529)

  • 1. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.
    Farnebo LO; Fuxe K; Goldstein M; Hamberger B; Ungerstedt U
    Eur J Pharmacol; 1971 Sep; 16(1):27-38. PubMed ID: 5157529
    [No Abstract]   [Full Text] [Related]  

  • 2. [The functional role of amantadine].
    Strömberg U; Svensson T
    Lakartidningen; 1972 Nov; 69(46):5340-2. PubMed ID: 4650742
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative.
    Svensson TH
    Eur J Pharmacol; 1973 Sep; 23(3):232-8. PubMed ID: 4746740
    [No Abstract]   [Full Text] [Related]  

  • 4. The mechanism of action of amantadine in Parkinsonism: a review.
    Bailey EV; Stone TW
    Arch Int Pharmacodyn Ther; 1975 Aug; 216(2):246-62. PubMed ID: 1180616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of dopamine from central noradrenaline nerves after treatment with reserpine plus amphetamine.
    Andén NE; Svensson TH
    J Neural Transm; 1973; 34(1):23-30. PubMed ID: 4714591
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of amantadine on motor activity and catalepsy in rats.
    Maj J; Sowińska H; Baran L
    Psychopharmacologia; 1972; 24(2):296-307. PubMed ID: 5064006
    [No Abstract]   [Full Text] [Related]  

  • 7. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on central and peripheral noradrenaline neurons using a new dopamine-(beta)-hydroxylase inhibitor.
    Corrodi H; Fuxe K; Hamberger B; Ljungdahl A
    Eur J Pharmacol; 1970 Oct; 12(2):145-55. PubMed ID: 5472868
    [No Abstract]   [Full Text] [Related]  

  • 9. Mode of action of L-DOPA on central noradrenaline mechanisms.
    Andén NE; Engel J; Rubenson A
    Naunyn Schmiedebergs Arch Pharmacol; 1972; 273(1):1-10. PubMed ID: 4260802
    [No Abstract]   [Full Text] [Related]  

  • 10. Uptake and accumulation of 3 H-6-hydroxydopamine in adrenergic nerves.
    Jonsson G; Sachs C
    Eur J Pharmacol; 1971 Sep; 16(1):55-62. PubMed ID: 5157530
    [No Abstract]   [Full Text] [Related]  

  • 11. [Uptake and storage of catecholamines by adrenergic fibers of the central and peripheral nervous system. II. Preferential retention of noradrenaline].
    L'Hermite P
    Arch Anat Microsc Morphol Exp; 1969; 58(3):257-82. PubMed ID: 4316936
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of reserpine on release of ( 3 H)noradrenaline, ( 3 H)dopamine and ( 3 H)metaraminol from field stimulated rat iris.
    Farnebo LO
    Biochem Pharmacol; 1971 Oct; 20(10):2715-26. PubMed ID: 5114507
    [No Abstract]   [Full Text] [Related]  

  • 13. Further studies on the mode of action of amantadine.
    Strömberg U; Svensson TH
    Acta Pharmacol Toxicol (Copenh); 1971; 30(3):161-71. PubMed ID: 5171936
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates.
    Fletcher EA; Redfern PH
    J Pharm Pharmacol; 1970 Dec; 22(12):957-9. PubMed ID: 4395527
    [No Abstract]   [Full Text] [Related]  

  • 15. [Specific fixation of noradrenaline on adrenergic nervous fibers].
    L'Hermite P; Israel M; Gautron J
    C R Seances Soc Biol Fil; 1969 Feb; 162(7):1267-71. PubMed ID: 4238869
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the uptake and accumulation of 3H-noradrenaline in adenergic nerves after pretreatment with reserpine, nialamide and a tyrosine-hydroxylase inhibitor.
    Hamberger B; Jonsson G; Almfors T; Sachs C
    Br J Pharmacol; 1968 Sep; 34(1):225P-226P. PubMed ID: 5676027
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
    Maj J; Sowińska H; Baran L; Sarnek J
    Eur J Pharmacol; 1974 Apr; 26(1):9-14. PubMed ID: 4857604
    [No Abstract]   [Full Text] [Related]  

  • 18. Localization of dopamine and norepinephrine in the medial basal hypothalamus of the rat.
    Kavanagh A; Weisz J
    Neuroendocrinology; 1973-1974; 13(4):201-12. PubMed ID: 4779325
    [No Abstract]   [Full Text] [Related]  

  • 19. Amantadine and catecholamine uptake.
    Herblin WF
    Biochem Pharmacol; 1972 Jul; 21(14):1993-5. PubMed ID: 4649347
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological properties of dehydroascorbic acid and ascorbic acid. Effects on the central and peripheral nervous systems in experimental animals.
    Sjöstrand SE
    Acta Physiol Scand Suppl; 1970; 356():1-79. PubMed ID: 5279048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.